A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

NCT05338775 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/ Refractory Multiple Myeloma

Interventions

DRUG: Talquetamab
DRUG: Teclistamab
DRUG: PD-1 Inhibitor

Sponsor

Janssen Research & Development, LLC